scholarly journals Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy

Rare Tumors ◽  
2011 ◽  
Vol 3 (1) ◽  
pp. 33-35 ◽  
Author(s):  
Hiroki Goto ◽  
Shotaro Hagiwara ◽  
Risen Hirai ◽  
Takahiko Miyama ◽  
Haruhito Honda ◽  
...  
Keyword(s):  
Stem Cell ◽  
Antiretroviral Therapy ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Highly Active Antiretroviral Therapy ◽  
Plasmablastic Lymphoma ◽  
Highly Active

Comparable survival between HIV+ and HIV− non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation

Blood ◽  
2009 ◽  
Vol 113 (23) ◽  
pp. 6011-6014 ◽  
Author(s):  
José L. Díez-Martín ◽  
Pascual Balsalobre ◽  
Alessandro Re ◽  
Mariagrazia Michieli ◽  
José M. Ribera ◽  
...  
Keyword(s):  
Stem Cell ◽  
Antiretroviral Therapy ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Highly Active Antiretroviral Therapy ◽  
Bacterial Infections ◽  
Progression Free Survival ◽  
Highly Active ◽  
Total Body

AbstractAutologous stem cell transplantation (ASCT) has been successfully used in HIV-related lymphoma (HIV-Ly) patients on highly active antiretroviral therapy. We report the first comparative analysis between HIV-Ly and a matched cohort of HIV− lymphoma patients. This retrospective European Group for Blood and Marrow Transplantation study included 53 patients (66% non-Hodgkin and 34% Hodgkin lymphoma) within each cohort. Both groups were comparable except for the higher proportion of males, mixed-cellularity Hodgkin lymphoma and patients receiving granulocyte colony-stimulating factor before engraftment and a smaller proportion receiving total body irradiation-based conditioning within the HIV-Ly cohort. Incidence of relapse, overall survival, and progression-free survival were similar in both cohorts. A higher nonrelapse mortality within the first year after ASCT was observed in the HIV-Ly group (8% vs 2%), predominantly because of early bacterial infections, although this was not statistically significant and did not influence survival. Thus, within the highly active antiretroviral therapy era, HIV patients should be considered for ASCT according to the same criteria adopted for HIV− lymphoma patients.

Autologous stem cell transplantation for HIV-associated lymphoma

Blood ◽  
2001 ◽  
Vol 98 (13) ◽  
pp. 3857-3859 ◽  
Author(s):  
Amrita Krishnan ◽  
Arturo Molina ◽  
John Zaia ◽  
Auayporn Nademanee ◽  
Neil Kogut ◽  
...  
Keyword(s):  
Stem Cell ◽  
Antiretroviral Therapy ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Viral Loads ◽  
Non Hodgkin Lymphoma ◽  
Cd34 Cells ◽  
Cell Mobilization ◽  
Intensive Approach

Abstract Is peripheral stem cell mobilization followed by autologous stem cell transplantation (ASCT) feasible in patients with human immunodeficiency virus (HIV)– associated lymphoma (HIV-L)? Studies have demonstrated that, in the HIV- negative (HIV−) setting, ASCT may improve lymphoma-free survival in high-risk non-Hodgkin lymphoma (NHL) or relapsed Hodgkin disease (HD) and NHL. Given the poor prognosis of HIV-L with conventional chemotherapy, this dose-intensive approach was explored. Nine patients with HIV-HD or NHL mobilized a median of 10.6 × 106 CD34+ cells/kg and engrafted after ASCT. CD4 counts recovered to pretransplantation levels and HIV viral loads were controlled in patients compliant with antiretroviral therapy. Seven of 9 patients remain in remission from their lymphoma at a median of 19 months after transplantation. Thus, patients with HIV-L on antiretroviral therapy can engraft following ASCT. Prolonged lymphoma remissions, without significant compromise of immune function, can be seen, suggesting that ASCT can be used in selected patients with HIV-L.

Autologous stem cell transplantation for HIV-associated lymphoma

Blood ◽  
2001 ◽  
Vol 98 (13) ◽  
pp. 3857-3859 ◽  
Author(s):  
Amrita Krishnan ◽  
Arturo Molina ◽  
John Zaia ◽  
Auayporn Nademanee ◽  
Neil Kogut ◽  
...  
Keyword(s):  
Stem Cell ◽  
Antiretroviral Therapy ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Viral Loads ◽  
Non Hodgkin Lymphoma ◽  
Cd34 Cells ◽  
Cell Mobilization ◽  
Intensive Approach

Is peripheral stem cell mobilization followed by autologous stem cell transplantation (ASCT) feasible in patients with human immunodeficiency virus (HIV)– associated lymphoma (HIV-L)? Studies have demonstrated that, in the HIV- negative (HIV−) setting, ASCT may improve lymphoma-free survival in high-risk non-Hodgkin lymphoma (NHL) or relapsed Hodgkin disease (HD) and NHL. Given the poor prognosis of HIV-L with conventional chemotherapy, this dose-intensive approach was explored. Nine patients with HIV-HD or NHL mobilized a median of 10.6 × 106 CD34+ cells/kg and engrafted after ASCT. CD4 counts recovered to pretransplantation levels and HIV viral loads were controlled in patients compliant with antiretroviral therapy. Seven of 9 patients remain in remission from their lymphoma at a median of 19 months after transplantation. Thus, patients with HIV-L on antiretroviral therapy can engraft following ASCT. Prolonged lymphoma remissions, without significant compromise of immune function, can be seen, suggesting that ASCT can be used in selected patients with HIV-L.

Sign in / Sign up

Export Citation Format

Share Document